Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 12/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21570869 | 0.98 | TSHR (0.48) | TSHRALDH1A1CYP3A4EPHX1ACHE | |
| SCHEMBL7534754 | 0.90 | EPHX1 (0.61) | TSHREPHX1ACHEHPGD | |
| SCHEMBL3663445 | 0.90 | EPHX1 (0.61) | TSHREPHX1ACHEHPGD | |
| SCHEMBL8997419 | 0.90 | EPHX1 (0.61) | TSHREPHX1ACHEHPGD | |
| SCHEMBL7534806 | 0.90 | EPHX1 (0.61) | TSHREPHX1ACHEHPGD | |
| SCHEMBL24090419 | 0.90 | ALDH1A1 (0.46) | TSHRALDH1A1CYP3A4EPHX1ACHE | |
| SCHEMBL11122001 | 0.88 | TSHR (0.41) | TSHRALDH1A1CYP3A4EPHX1ACHE | |
| SCHEMBL21787200 | 0.87 | ACHE (0.41) | TSHRALDH1A1CYP3A4EPHX1ACHE | |
| SCHEMBL5924841 | 0.85 | HPGD (0.57) | TSHRALDH1A1EPHX1ACHEHPGD | |
| SCHEMBL7513891 | 0.84 | EPHX2 (0.40) | TSHRALDH1A1CYP3A4EPHX1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424965-B1 | CROSSLINK AGENTS AND ITS USE | BAUSCH & LOMB (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3424965-A1 | CROSSLINK AGENTS AND DUAL RADICAL CURE POLYMER | Bausch & Lomb Incorporated (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-2167555-B1 | CROSSLINK AGENTS AND DUAL RADICAL CURE POLYMER | BAUSCH & LOMB (US) | 2018-10-10 | — | — | EP | disclosed |
| US-8252850-B2 | Crosslink agents | BAUSCH & LOMB INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-20110105779-A1 | CROSSLINK AGENTS | ORAPHARMA, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7901073-B2 | Silicone hydrogel with composite hydrophilic and silicone polymers prepared with selective crosslink agents | BAUSCH & LOMB INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090018233-A1 | Crosslink Agents and Dual Radical Cure Polymer | SOLTA MEDICAL, INC. | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105779-A1 | CROSSLINK AGENTS | UACA, CRYAA, DCLRE1A | TSHR 3185/4885ALDH1A1 2278/4885CYP3A4 4579/4885 |
| US-20090018233-A1 | Crosslink Agents and Dual Radical Cure Polymer | UACA, CRYAA, RAD51 | TSHR 2555/4885ALDH1A1 1327/4885CYP3A4 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.